Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
0.768
-0.046 (-5.73%)
Nov 21, 2024, 10:59 AM EST - Market open
Seres Therapeutics Revenue
Seres Therapeutics had revenue of $126.33M in the twelve months ending September 30, 2024, down -0.72% year-over-year. In the year 2023, Seres Therapeutics had annual revenue of $126.33M with 1,672.24% growth.
Revenue (ttm)
$126.33M
Revenue Growth
-0.72%
P/S Ratio
0.93
Revenue / Employee
$542,167
Employees
233
Market Cap
130.63M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 126.33M | 119.20M | 1,672.24% |
Dec 31, 2022 | 7.13M | -137.80M | -95.08% |
Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
American Well | 254.04M |
TELA Bio | 68.65M |
Journey Medical | 57.77M |
Fennec Pharmaceuticals | 49.35M |
Protalix BioTherapeutics | 45.67M |
InflaRx | 187.93K |
MCRB News
- 8 days ago - Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - GlobeNewsWire
- 7 weeks ago - Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A - GlobeNewsWire
- 7 weeks ago - Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé - Business Wire
- 7 weeks ago - Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30 - GlobeNewsWire
- 2 months ago - Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade - Seeking Alpha
- 2 months ago - Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) - GlobeNewsWire